Mucopolysaccharidosis
Links shared publicly online about this topic
Neurology Article | Mucopolysaccharidosis
mdlinx.com — “Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II” View full resource at mdlinx.com
Most Recently Shared on May 4, 2011 at 11:12 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II: Pediatrics http://bit.ly/mBpTfB #neuro
Neurology Article | Mucopolysaccharidosis
mdlinx.com — “Early Clinical Markers of Central Nervous System Involvement in Mucopolysaccharidosis Type II” View full resource at mdlinx.com
Most Recently Shared on May 14, 2011 at 3:48 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Early Clinical Markers of Central Nervous System Involvement in Mucopolysaccharidosis Type II: The Journa... http://bit.ly/iIVIu7 #neuro
Mucopolysaccharidosis Type II: eMedicine Pediatrics: Genetics and Metabolic Disease
emedicine.medscape.com — “Overview: Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation ...” View full resource at emedicine.medscape.com
Most Recently Shared on July 15, 2009 at 9:36 pm By:
Medscape Pediatrics Pediatrics and Health Site
Mucopolysaccharidosis Type II article over at eMedicine has been updated. http://bit.ly/VTYYW #genetics #pediatrics #health #medicine
Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated ... http://bit.ly/aZlrBz
www3.interscience.wiley.com — “Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated ... http://bit.ly/aZlrBz” View full resource at www3.interscience.wiley.com
Most Recently Shared on August 5, 2010 at 12:25 pm By:
Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated ... http://bit.ly/aZlrBz
Mucopolysaccharidoses Types I-VII: eMedicine Dermatology
emedicine.medscape.com — “Overview: Mucopolysaccharidoses (MPSs) are a group of lysosomal storage diseases, each of which is produced by an inherited deficiency of an enzyme involved in the degradation of acid mucopolysaccharides, now called glycosaminoglycans (GAGs). These diseases are autosomal ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 21, 2010 at 10:43 pm By:
Susan Scroggins Health Advocate and Active Health Library
Mucopolysaccharidoses (MPSs) are a group of lysosomal storage diseases. Learn about each type. http://bit.ly/b5hw00
Cardiology Medical News about Echocardiography
mdlinx.com — “Echocardiographic study of paediatric patients with mucopolysaccharidosis” View full resource at mdlinx.com
Most Recently Shared on May 15, 2010 at 4:33 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Echocardiographic study of paediatric patients with mucopolysaccharidosis: Cardiology in the Young http://bit.ly/ajZhmI #cardio #mdlinx
Winchester Syndrome: eMedicine Dermatology
emedicine.medscape.com — “Overview: Winchester syndrome (WS) is a syndrome of pathologic changes consisting of dwarfism (resulting from disturbances of the skeletal-articular system), corneal opacities, coarsening of facial features, leathery skin, and hypertrichosis. In 1969, Winchester et al first described ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 21, 2010 at 11:43 pm By:
Julie Bohlen Health Executive and Active Health Library
Winchester syndrome (WS) is a syndrome of pathologic changes consisting of dwarfism, eye problems, and skin changes. http://bit.ly/cnJfVE
New Discovery Prevents Symptoms Of Rare Genetic Disorder
medicalnewstoday.com — “A new study offers hope for children born with a rare genetic disease, according to a paper published by the American Association for the Advancement of Science.The research was led by Dr” View full resource at medicalnewstoday.com
Most Recently Shared on December 5, 2010 at 1:05 pm By:
New Discovery Prevents Symptoms Of Rare Genetic Disorder http://mnt.to/3Nyr #genetics
Research Supports Newborn Screening And Early Treatment For Rare Genetic Disorder, MPS I
medicalnewstoday.com — “In a study that supports the need for newborn screening and early treatment for a rare genetic disorder, researchers at Los Angeles Biomedical Research Institute (LA BioMed) and Iowa State Univers” View full resource at medicalnewstoday.com
Most Recently Shared on December 2, 2010 at 12:33 pm By:
Research Supports Newborn Screening And Early Treatment For Rare Genetic Disorder, MPS I http://ow.ly/1agzbQ
Newborn Screening and Early Treatment for Rare Genetic Disorder - Health News - redOrbit
redorbit.com — “Researchers believe that newborn screening and early treatment for a rare genetic disorder, mucopolysaccharidosis type I (MPS I), is needed so that enzyme replacement therapy can begin at birth and eliminate all the symptoms associated with MPS I.” View full resource at redorbit.com
Most Recently Shared on December 29, 2010 at 4:43 pm By:
Newborn Screening and Early Treatment for Rare Genetic Disorder: (Ivanhoe Newswire) – Researchers believe that n... http://bit.ly/h27iJP
Phase 3 study of GALNS for the treatment of Morquio A Syndrome - MPR
empr.com — “BioMarin Pharmaceuticals announced that it has initiated a Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.” View full resource at empr.com
Most Recently Shared on February 2, 2011 at 5:45 pm By:
MPR News: Phase 3 study of GALNS for the treatment of Morquio A Syndrome: BioMarin Pharmaceuticals announced tha... http://bit.ly/ic0Z8g
Phase 3 study of GALNS for the treatment of Morquio A Syndrome - ONA
oncologynurseadvisor.com — “BioMarin Pharmaceuticals announced that it has initiated a Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.” View full resource at oncologynurseadvisor.com
Most Recently Shared on February 2, 2011 at 5:14 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of GALNS for the treatment of Morquio A Syndrome http://goo.gl/fb/VGL7E
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Medscape Pediatrics
Latest medical news, articles, and features from Medscape Pediatrics
Advertisement
